FDA-Approved drug tested to restore vision in genetic color blindness
NCT ID NCT04041232
Summary
This early-stage study is testing whether an existing drug called glycerol phenylbutyrate (PBA) can improve vision in people with a rare, inherited form of color blindness caused by a specific gene mutation (ATF6). Two adult patients will take the drug three times a day and have their vision and eye health closely monitored over several clinic visits. The goal is to see if PBA can reduce cellular stress in the eye and improve retinal function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHROMATOPSIA 7 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.